Skip to main content
Clinical Trials/CTRI/2023/06/054339
CTRI/2023/06/054339
Not yet recruiting
Phase 2

Study to develop a validated tool for the assessment of ama, and to assess the effect of amapachana medicines - Musta (Cyperus rotundus Linn.) as add on to conventional treatments in patients of Primary Myelofibrosis and the expression of inflammatory markers at molecular level â?? An open label randomized controlled clinical study

All India Institute of Ayurveda0 sites0 target enrollmentTBD

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Health Condition 1: D471- Chronic myeloproliferative disease
Sponsor
All India Institute of Ayurveda
Status
Not yet recruiting
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional

Investigators

Eligibility Criteria

Inclusion Criteria

  • 1\.Subjects willing to participate \& able to give informed consent
  • 2\.Newly diagnosed cases (Diagnosed within 3months and treatment naïve) of Primary Myelofibrosis
  • 3\.JAK2 V617 mutation positive (Annexure 5\)
  • 4\.Symptomatic and requiring treatments
  • 5\.Eligible for treatment with either of JAK2 inhibitors, Hydroxyurea or Thalidomide

Exclusion Criteria

  • 1\.Psychiatric patients on treatment
  • 2\.Patients with co\-morbidities like Hypertension, DM etc
  • 3\.Pregnant women and lactating mothers
  • 4\.Who are unable to take oral medications
  • 5\.SRSF2, ASXL1, and U2AF1\-Q157 mutations
  • 6\.3 times increased creatinine levels than the normal
  • 7\.Hb less than 8g/ dl
  • 8\.Leucocytes greater than 25\.10(9\)/L
  • 9\.Esophageal varices, bleeding, Ascites

Outcomes

Primary Outcomes

Not specified

Similar Trials